NO functions as an endothelium-derived relaxing factor by activating guanylate cyclase to increase cGMP levels. However, NO and related species may also regulate vascular tone by cGMP-independent mechanisms. We hypothesized that naturally occurring NO donors could decrease the pulmonary vascular response to serotonin (5-HT) in the intact lung through chemical interactions with 5-HT2 receptors. In both isolated rabbit lung preparations and isolated pulmonary artery (PA) rings, Snitrosoglutathione (GSNO) (50 to 250 µM) inhibited the response to 5-HT (0.01 to 10 µM). The vasoconstrictor response to 5-HT was mediated by 5-HT2 receptors in the lung since it could be blocked completely by the selective inhibitor ketanserin (10 µM).
INTRODUCTION
Nitric oxide (NO) is an endothelium-derived relaxing factor, which counteracts the effects of vasoconstrictors under physiological conditions to maintain low pulmonary vascular tone. NO produces vasodilation by activating guanylate cyclase to increase cGMP levels (30). There is substantial evidence that NO also relaxes vascular smooth muscle by cGMP-independent pathways. cGMP-independent effects of NO on vascular smooth muscle can be mediated by stimulating Na + -K + -ATPase activity, modifying K+ channels, or decreasing sensitivity to or release of vasoconstrictors (6, 8) (21) (36) (18, 19) (10, 14) .
The vasoconstrictor effect of serotonin in the lung can be inhibited with NO. In the pulmonary vasculature, 5-HT binds to G-protein coupled receptors (GPCR), including 5-HT1B and 5-HT2A receptors, to produces vasoconstriction (27) (28) (23) (31, 45) . NO inhibits the response to 5-HT in several vascular tissues including human umbilical arteries (35) (42) , bovine coronary arteries (11) and rat pulmonary artery (44) . Although the vascular response to 5-HT is altered by NO, the mechanisms by which NO modifies the responses to 5-HT and their importance in the lung are not known.
The effects of NO on cellular function are mediated by its reactions with specific molecular targets. NO can exist in several oxidation-reduction states (e.g. NO -, NO•, NO + ), which promote its reactions with protein thiols, transition metals such as iron in heme-proteins, O 2 , and reactive oxygen species. The biochemical reactions of NO have been shown to both activate and inactivate protein function and alter receptor activity.
(20) (38) (37).
G-protein coupled receptors are known targets of NO via cGMP-independent pathways. Studies of β 2 -adrenergic receptors in cultured cells have shown that NO donors reduce signaling by β 2 -adrenergic agonists and promote depalmitoylation of the receptor (1) (40) (43) . In the m2 muscarinic GPCR and angiotensin (AT 1 ) GPCR, treatment with NO inhibits receptor-ligand binding (2) (8) . The role of NO in modifying the response to 5-HT receptor function has not been investigated previously.
We hypothesized that naturally occurring NO donors could decrease the pulmonary vascular response to 5-HT in the intact lung through chemical interactions involving the receptor pathway. In this study, we characterized the response to 5-HT in intact rabbit lungs and isolated PA rings and determined that vasoconstriction in our model was mediated by the 5-HT2 receptor. We studied the effects of the NO donor, nitrosoglutathione (GSNO) on the 5-HT response and interrogated the mechanism of 5-HT inhibition. Our findings are consistent with chemical modification by NO of the 5-HT2 G-protein coupled receptor system to inhibit vasoconstriction by a reversible thiolbased mechanism.
MATERIALS AND METHODS

Reagents and Pharmaceuticals. All chemicals were obtained from Sigma Chemical
Company (St. Louis, MO) unless otherwise specified.
Isolated Lung Preparation.
These experiments were performed in isolated bufferperfused lungs (IPL) of rabbits as previously described (34) The perfusion circuit contained a reservoir suspended freely from a force transducer (Model FT100, Grass Instrument Company, Quincy, MA) and a water heater set at 37°C. Perfusate was circulated by a roller pump (Sarns, Inc., Ann Arbor, MI) and passed through a bubble trap before entering the pulmonary artery. The perfusate returned to the left atrium and then to the reservoir, which was set at the lowest portion of the lung to provide a left atrial pressure of zero. Perfusion began slowly and was gradually increased to 100 ml/min. After rinsing the lungs free of blood with 500 ml buffer, a re-circulating system was established. The total volume of KH buffer in the circuit was approximately 250 ml. Mean pulmonary artery pressure (Ppa) and tracheal pressure (Paw) were measured using pressure transducers (P231D, Gould Statham Instruments, Inc., Hato Ray, PR). The weight gain (WG) of the lung as an index of pulmonary edema formation was measured as the loss of perfusate from the reservoir connected to the force transducer. Ppa, Paw and WG were continuously recorded on a four-channel recorder (Model 2450S, Gould Inc., Cleveland, OH). The preparation was considered successful if the Ppa was stable between 10 and 20 torr and there was less than 0.15 g/min weight gain during a ten-minute stabilization period.
Pulmonary Artery Ring Preparation. Pulmonary artery rings (3 mm) were harvested from New Zealand white rabbits and mounted in 25 ml tissue baths filled with Krebs
Henseleit buffer and bubbled with 21% O 2 / 5% CO 2 . Isometric tension was measured.
All rings in the study were suspended with similar baseline levels of tension (∼2 g).
Tissue baths were thoroughly rinsed with fresh buffer between interventions.
Synthesis of GSNO. GSNO was synthesized as previously described (7). Briefly, GSNO was prepared by reacting reduced glutathione (GSH) dissolved in 0.5 N HCl with equimolar sodium nitrite dissolved in water. GSNO used in IPL experiments was precipitated with acetone, filtered and washed sequentially with water, acetone and ether.
Solutions of GSNO in KH buffer were prepared daily from precipitated samples and concentration was confirmed by absorption spectroscopy at 335 nm using an extinction coefficient of .92 OD/mM/cm. In isolated ring experiments, GSNO was prepared from stock solutions of GSH and sodium nitrite immediately prior to use in tissue baths.
Measurements of NOx level. Perfusate was assayed for NOx (nitrite and nitrate) using a catalytic method for reduction of NO oxidation products to NO gas. Perfusate samples were injected into a refluxing glass reaction chamber containing vanadium ( 
Statistical Analysis.
Data were analyzed by analysis of variance (ANOVA) with repeated measures for experiments in isolated lungs and dose response curves in rings.
All other data were analyzed by ANOVA followed by the Fisher protected least square difference test using a commercially available software program (Statview512+, Brain
Power Company, Calabasas, CA). Data were expressed as mean ± standard error (SE).
The p values have been provided where statistical tests were performed. (Fig 1B) .
RESULTS
Dose
Effects of the 5-HT2 receptor antagonist ketanserin on the response to 5-HT.
Ketanserin (10 µM) virtually abolished the vasoconstrictor response to 5-HT (1 µM) in the rabbit IPL (Fig 2) . The change in Ppa with 5-HT at five minutes was 0.5 ± 0.2 mm Hg for lungs pretreated with ketanserin compared with 11.5 ± 3.9 mm Hg in control lungs (p<0.05). These results indicate that the constrictor response to 5-HT is mediated by the 5-HT2A receptor, which is present in the pulmonary vasculature (27).
Effects of GSNO donors on the response to 5-HT in IPL. Pretreatment with GSNO
markedly inhibited the vasoconstrictor response to 5-HT in IPL (Fig 3) . A qualitatively similar result was found using SIN-1. The change in Ppa with 5-HT after five minutes was 2.6 ± 1.1 mm Hg for lungs pretreated with GSNO (50 µM) (23 % of control 5-HT response) and 1.6 ± 0.7 mm Hg for lungs pretreated with SIN-1 (100 µM) (14% of control 5-HT response) (p<0.05 for each NO donor vs. control). There was no statistical difference in baseline Ppa in IPL pretreated with GSNO or SIN-1. NOx levels in the perfusate measured by chemiluminescence were higher in both NO donor groups compared to control but similar to each other (Table 1) Effects of NO donors on the response to 5-HT in pulmonary artery rings. In rabbit pulmonary artery rings, the increase in ring tension was the same with two sequential doses of 1 µM 5-HT. Similar to IPL, the response to 5-HT in rings was nearly eliminated by 10 µM ketanserin, a 5-HT2 receptor antagonist (data not shown). As in the intact lung, the response to 5-HT also was significantly reduced after pretreatment with 250 µM GSNO (18 ± 3% of initial 5-HT response)(n=5, p<0.05 vs control rings) or 500 µM SIN-1 (27 ± 5% of initial 5-HT response) (n=8, p<0.05 vs control rings) (Fig 7A) . The dose response curve to 5-HT (0.01 -10 µM ) for control rings was significantly attenuated in GSNO treated rings (n=4, p<0.05) (Fig 7B) . GSH or GSSG at the equivalent concentrations (250 µM and 125 µM, respectively) had no effect on the response to 5-HT (data not shown). The dose response curve to 5-HT (0.01 -1 µM) was shifted to the left in PA rings treated with the guanylate cyclase inhibitor, LY-83583 (10 µM). GSNO (250 µM) prevented 90% of the response to 0.1 µM 5-HT and 40% of the response to 1.0 µM 5-HT in rings treated with LY-83583, indicating an effect of GSNO that was independent of guanylate cyclase activity (n = 3, p<0.05) (Fig. 8) Ability of DTT to reverse the inhibitory effects of GSNO on the 5-HT response. The thiol reducing agent, DTT (10 mM), partially restored the response to 5-HT (1 µM) in isolated rings treated with GSNO (250 µM) (38 ± 8 % of initial 5-HT response)(n= 7, p<0.05 vs GSNO treated rings) (Fig 9) . In SIN-1-treated rings (500 µM), there was a trend toward restoration of the response, but the effect was not statistically significant (32 ± 6% of initial 5-HT response)(n=9, p=0.2). DTT did not change the response in control rings (95 ± 9 % of initial 5-HT response)(n=6). Overall, the response to 5-HT following DTT in GSNO-treated rings increased 2.6-fold vs. a 0.5-fold increase after DTT in SIN-1 treated rings.
DISCUSSION
NO binds to thiol and metal centers in proteins to regulate protein function (38) .
NO may function as an endothelial-derived relaxing factor by activating guanylate cyclase in smooth muscle to decrease vascular tone, or by chemically modifying vasoconstrictor agents, their receptor proteins, or contractile components in smooth muscle to prevent vasoconstriction. We examined the effects of NO donors on vasoconstriction induced by two potent pulmonary vasoconstrictors of physiological and pathophysiological relevance, 5-HT and ET-1, which bind to distinct receptors within the superfamily of G-protein-coupled receptors, but operate in vascular smooth muscle using the same intracellular transduction mechanisms (23).
In this study, 5-HT produced vasoconstriction in isolated rabbit lungs and pulmonary artery rings. The effect of 5-HT was inhibited by ketanserin, a specific antagonist of the 5HT2A receptor. These findings are consistent with earlier studies demonstrating that ketanserin-sensitive 5HT2A receptors in pulmonary artery smooth Another potential target for NO is the 5-HT transporter (5-HTT), which is necessary for uptake and metabolism of 5-HT by the lung and is involved in pulmonary vascular smooth muscle cell proliferation (12, 13, 26) . In our study, inhibition of the 5-HTT with fluoxetine did not restore 5-HT vasoconstriction following treatment with GSNO. Therefore, the inhibitory effects of the NO donors were not attributable to enhancement of 5-HT uptake by the lung.
The pulmonary vasoconstrictor effects of endothelin (ET-1), which are also mediated through a G-protein-coupled receptor linked to phospholipase C, were not inhibited by GSNO or SIN-1. GSNO therefore inhibits vasoconstriction by 5-HT by modifying the response at a target(s) proximal to phospholipase C, most likely the 5-HT2
receptor. Activation of phospholipase C liberates two second messengers, diacylglycerol (DAG) and inositol triphosphate (IP3), which stimulates calcium influx and mobilizes intracellular calcium from the sarcoplasmic reticulum to produce vasoconstriction (23).
In PA smooth muscle cells, NO inhibited 5-HT-induced calcium release by both IP3 and DAG, supporting our conclusion that the site of action for NO in the 5-HT pathway is proximal to phospholipase C (44).
The present data strongly suggest that NO modifies the 5HT2A G-protein coupled In pulmonary artery rings, GSNO inhibited the constrictor response to 5-HT, and the inhibitory effect of GSNO was largely reversible by the thiol reductant, DTT.
Nitrosothiol compounds like GSNO have NO + character that promotes trans-nitrosylation of other protein thiols. Reversal by DTT indicates that GSNO probably modified the 5-HT response by thiol nitrosylation. Specific acidic and/or basic amino acid sequences surrounding a given Cys favors S-nitrosylation (3, 39) , and the 5-HT2 receptor contains several Cys predicted to be susceptible to S-nitrosylation (39) .
In contrast to GSNO, the NO donor SIN-1 modified the 5-HT response by a DTTresistant mechanism. SIN-1 produces different chemical modifications than GSNO, e.g nitration rather than S-nitrosylation. Thus the fate of NO released by SIN-1 may better represent chemical reactions associated with increased oxidative stress and pathological ONOO -formation. We did not determine, however, whether a specific S-nitrosylation event is responsible for the effects of GSNO. An alternative chemical explanation, that S-thiolation e.g. glutathiolation, was responsible for the more potent effects of GSNO than SIN-1 cannot be distinguished from S-nitrosylation in these studies. However, lack of effect of GSSG argues against S-thiolation.
In summary, GSNO reversibly inhibits the response to 5-HT in the intact lung.
The experimental data narrow the target of NO to the level of thiol residues on the G- Control (n=4) GSNO (n=5) SIN-1 (n=5) NOx (uM) 3.5 ± 0.7 30.5 ± 5.0 24.6 ± 3.1 Table 1 : NOx levels in perfusate prior to administration to 5-HT increased to similar levels following 50 minutes treatment with either GSNO (50 uM) or SIN-1 (100 uM).
